Ensysce Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 9
- Market Cap
- $5.4M
- Website
- http://www.ensysce.com
- Introduction
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of solutions for severe pain relief while reducing the fear of and the potential for misuse and overdose. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company was founded in April 2003 and is headquartered in La Jolla, CA.
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)
- First Posted Date
- 2024-10-07
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT06629402
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
PF614 Analgesic Activity in Acute Postoperative Pain
- Conditions
- Postoperative PainPostoperative Pain, Acute
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 300
- Registration Number
- NCT06602271
Single and Multi-Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
- Conditions
- Pharmacokinetics
- Interventions
- Drug: PF614 capsule
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 50
- Registration Number
- NCT06500793
- Locations
- 🇺🇸
Quotient Sciences, Miami, Florida, United States
A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users
- Conditions
- Recreational Drug Use
- Interventions
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 32
- Registration Number
- NCT05571345
- Locations
- 🇺🇸
Dr. Vince Clinical Research, Overland Park, Kansas, United States
A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users
- Conditions
- Recreational Drug Use
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Ensysce Biosciences
- Target Recruit Count
- 27
- Registration Number
- NCT05567354
- Locations
- 🇺🇸
Ohio Clinical Trails, Columbus, Ohio, United States
- Prev
- 1
- 2
- Next
News
Ensysce Biosciences Secures Patent for Novel Opioid Use Disorder Treatment PF9001
Ensysce Biosciences received a U.S. patent for PF9001, a methadone prodrug designed to treat opioid use disorder with reduced cardiotoxicity and overdose risks.
Ensysce Biosciences Strengthens Regulatory Team Ahead of Critical Phase 3 Trials and NDA Submission
Ensysce Biosciences has appointed Tracy Hysong, CCRA, as Senior Director of Regulatory Affairs to support multiple clinical trials and upcoming regulatory submissions for its novel pain medications.
Ensysce Biosciences Secures Patent for Novel Methadone-Based Opioid Use Disorder Treatment
Ensysce Biosciences has received a U.S. patent for PF9001, a new methadone prodrug designed to treat opioid use disorder with reduced risks of cardiotoxicity and overdose.
Ensysce Biosciences Pioneers Novel Opioids with Built-in Overdose Prevention Technology
Ensysce Biosciences has developed chemically modified oxycodone that remains inactive unless taken orally, significantly reducing abuse potential while maintaining pain relief efficacy.
Ensysce Biosciences Advances Abuse-Resistant Opioids PF614 and PF614-MPAR Towards Market
Ensysce Biosciences reports significant progress in its clinical programs for PF614 and PF614-MPAR, designed for safer pain relief with reduced abuse potential.
Ensysce Biosciences Secures Supply and Partnership to Advance Abuse-Resistant Pain Relief
Ensysce Biosciences partners with a specialty drug manufacturer for the development and commercial launch of PF614 and PF614-MPAR, aiming for efficient regulatory approval.
Ensysce Biosciences' PF614-MPAR Demonstrates Overdose Protection in Clinical Trial
Ensysce Biosciences' PF614-MPAR shows overdose protection in a Phase 1b clinical trial, reducing oxycodone blood concentration.
Ensysce Biosciences Advances Novel Analgesics PF614 and PF614-MPAR Towards Phase 3 Trials
Ensysce Biosciences is advancing PF614, an extended-release oxycodone, towards Phase 3 trials after positive clinical trial data and FDA discussions.
Ensysce Biosciences Advances Abuse-Deterrent and Overdose-Protection Opioid Programs
Ensysce Biosciences is focused on developing next-generation opioid products with abuse-deterrent and overdose protection features using its TAAP™ and MPAR™ technology platforms.